Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HL-300 Ointment in Mild-to-Moderate Atopic Dermatitis
NCT07629778Phase 2Recruiting
- Sponsor
- Hangzhou Highlightll Pharmaceutical Co., Ltd.
- Start
- May 2026
- Primary completion
- Jun 2027
- Countries
- 1
01
Overview
A Phase 2 trial of HL-300 in atopic dermatitis (AD), sponsored by Hangzhou Highlightll Pharmaceutical Co., Ltd.. Started May 2026; status: recruiting.
02
Drugs
HL-300
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT07629778.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07629778.